The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | HORIZON study: EMD subgroup analysis
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase II HORIZON study (NCT02963493), investigating melflufen plus dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD). This patient subgroup has a highly unmet medical need with very poor prognosis and clinical outcomes. The combination of dex and melflufen, a first-in-class peptide-drug conjugate (PDC), showed clinically meaningful efficacy, as well as a manageable safety profile. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
